Product Description
Mechanisms of Action: Thrombin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Brazil | Germany | Italy | Portugal | Sweden
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hip Fracture|Thromboembolism
Phase 2: Atrial Fibrillation|Stroke
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2004-002746-35 | P3 |
Completed |
Hip Fracture |
2006-08-29 |
|
EXTEND | P3 |
Terminated |
Thromboembolism |
2006-08-01 |
|
SH-TPA-0004 | P2 |
Terminated |
Atrial Fibrillation|Stroke |
2004-06-01 |